Mélanie

MD, Medical Oncologist, Physician #GUcancer #Research

[Giuseppe Procopio @g_procopio_]

Does local treatment of the primary tumour still add value in #mHSPC patients receiving ARPIs? Our latest expert opinion examines the evidence, ongoing controversies and future directions in the intensification era.

Article here: https://t.co/J1UAPcx9dI

#Genitourinary #Prostate

[Giuseppe Procopio @g_procopio_]

More about #RareHistology GU tumors at @IstTumori: update on academic trials by @MelClaps and multidisciplinary discussion because rare doesn’t mean less important.

#ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026

[Mélanie @MelClaps]

Our research on #renalcellcarcinoma: prospective data about #TKI efficacy after #immunecheckpointinhibitors

#sequencestrategy #cabozantinib #secondline #ccRCC

doi: 10.1177/03008916221138881

@gippo27 @elena_verzoni @pierangelasepe @UgoDeGiorgi @DrIacovelli @meeturoIT

[Tumori Journal @TumoriJ]

🎙️ #Podcast Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial evaluating efficacy and safety of #cabozantinib for patients with metastatic #renalcellcarcinoma👇

🎙️https://t.co/8AyIIAJ23T

To the article 🔗https://t.co/bzMluYC07D

#kcsm

[Meet-URO @meeturoIT]

Ready for @ASCO #GU23!
Here's Meet-URO selection of the hot topics and key presentation.

Looking forward to exciting data presented in San Francisco.

Congrats to the @meeturoIT group for the selected works!

[Tom Powles @tompowles1]

COSMIC313 cabo/ipi/nivo vs ipi/nivo in 1st line RCC. ⬆️ FU & ⬆️ numbers show continued strong PFS signal:HR 0.74.Exploratory analysis show benefit for triplet mainly in intermediate risk .This is not due to ⬇️ drug exposure. Maybe VEGF treatment ⬇️ active in poor risk #GU23

[Mélanie @MelClaps]

Proud of being part of this Team 😎 #collectingductcarcinoma #rarecancer #renalcancer #research

[Tumori Journal @TumoriJ]

Collecting duct carcinoma is a rare type of non–clear cell renal cell carcinoma
Authors present analysis from BONSAI-2⃣ study👉#Nivolumab as therapeutic option after #cabozantinib failure in #mCDC Pts

🔗https://t.co/yw9fhEfCSO

@gippo27 @MelClaps @pierangelasepe @elena_verzoni

[Tumori Journal @TumoriJ]

Dr Mélanie Claps, @IstTumori GU Cancers Unit, about👇

Multicenter phase2⃣ single arm study of #cabozantinib in Pts w/ advanced or unresectable #renalcellcarcinoma pre-treated w/ one immune-checkpoint inhibitor ➡️ The BREAKPOINT trial (Meet-Uro trial 03)

https://t.co/bzMluYC07D

[Tumori Journal @TumoriJ]

@gippo27 @MelClaps @ChiaraPircher @pierangelasepe @UgoDeGiorgi @DrIacovelli @elena_verzoni @meeturoIT et al

#GUcancers #kcsm

https://t.co/c2I5DHvKBw

[Mélanie @MelClaps]

@jamesbibarnes @marvelusbucky @BuckvBarnes_ @aboutgio_ Grazie!!! 😍 qualcuno che mi capisce!

[Mélanie @MelClaps]

Our research on kidney cancer 😊